Press-release for stocks for LMDX

Prices are updated after-hours

| -98.14% | O: 7.91% H: 13.15% C: 12.07%
care europe technology diagnostics innovation

| -99.81% | O: -0.85% H: 11.78% C: 11.17%
sars-cov-2

LumiraDx Reports Third Quarter 2022 ResultsProgress on Near-Term Growth Opportunities and Cost Savings
Published: 2022-11-09 (Crawled : 13:00) - biospace.com/
LMDX | $0.016 -15.0% 130M

| -98.4% | O: -0.91% H: 16.16% C: 11.11%
growth

LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published: 2023-04-24 (Crawled : 21:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M

| -97.35% | O: -2.19% H: 18.64% C: 6.78%
nasdaq

| -99.59% | O: 3.35% H: 12.22% C: 6.73%
star sars-cov-2

LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 11
Published: 2022-04-29 (Crawled : 12:20) - biospace.com/
LMDX | $0.016 -15.0% 130M

| -99.65% | O: -0.22% H: 5.26% C: 4.82%
conference results

| -99.57% | O: 0.81% H: 6.67% C: 4.8%
care test growing diagnostic diabetes platform

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
Published: 2022-11-14 (Crawled : 08:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M

| -98.49% | O: -0.94% H: 15.24% C: 4.76%
expansion test commercial rapid

| -98.31% | O: -0.5% H: 4.24% C: 4.24%
care test commercial health heart

LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Published: 2023-01-31 (Crawled : 22:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M

| -98.31% | O: -0.5% H: 4.24% C: 4.24%
nasdaq

LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
LMDX | $0.016 -15.0% 130M

| -99.82% | O: -0.23% H: 6.35% C: 2.96%
financial results results conference

LumiraDx CRP Test Achieves CE Marking
Published: 2022-01-11 (Crawled : 12:30) - biospace.com/
LMDX | $0.016 -15.0% 130M

| -99.82% | O: -1.95% H: 4.91% C: 2.92%
test

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
Published: 2022-01-14 (Crawled : 13:00) - biospace.com/
LMDX | $0.016 -15.0% 130M

| -99.83% | O: 0.0% H: 2.78% C: 1.95%
covid-19 covid test

LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
Published: 2022-05-20 (Crawled : 10:00) - biospace.com/
LMDX | $0.016 -15.0% 130M

| -99.59% | O: -2.81% H: 3.95% C: 1.84%
test sars-cov-2

LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering
Published: 2022-03-01 (Crawled : 12:30) - prnewswire.com
LMDX | $0.016 -15.0% 130M

| -99.78% | O: -9.84% H: 7.57% C: 1.06%
offering ces

| -98.53% | O: -2.75% H: 7.55% C: 0.94%
care growth

| -98.53% | O: -2.75% H: 7.55% C: 0.94%
care poc growth benefits

LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
Published: 2022-11-02 (Crawled : 12:20) - biospace.com/
LMDX | $0.016 -15.0% 130M

| -98.38% | O: 1.01% H: 5.0% C: 0.0%
conference financial results

LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements
Published: 2023-02-17 (Crawled : 22:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M